RZLT — Rezolute, Inc. Stock Price, Chart & AI Report

Positive May 11, 2026 • 11:00 UTC GlobeNewswire Inc. • Na

Rezolute to Participate in Upcoming Investor Conferences

Rezolute, Inc., a rare disease company focused on treating hyperinsulinism, announced it will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference (May 19, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The company will present oral results from its Phase 3 sunRIZE study of ersodetug in patients with congenital hyperinsulinism at the Pediatric Endocrine Society Annual Meeting, including previously announced topline results and additional continuous glucose monitoring-based outcomes showing significant improvements in glycemic control.

RZLT Rezolute ersodetug hyperinsulinism Phase 3 clinical trial sunRIZE study congenital hyperinsulinism investor conference

Sentiment note

The company is advancing its late-stage rare disease therapy with Phase 3 study results showing significant improvements in glycemic control. Participation in major investor conferences and oral presentation of positive clinical data demonstrates progress in drug development and investor engagement, which are positive indicators for the company's pipeline and market positioning.

Negative Apr 24, 2026 • 13:00 UTC GlobeNewswire Inc. • The Portnoy Law Firm

Rezolute, Inc. Investigated by the Portnoy Law Firm

Rezolute, Inc. (NASDAQ: RZLT) experienced a severe stock price collapse of 87.2% on December 19, 2025, following the announcement that its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in the Phase 3 sunRIZE clinical trial for congenital hyperinsulinism. The drug failed to demonstrate statistically significant efficacy over placebo, prompting a securities fraud investigation by the Portnoy Law Firm.

RZLT clinical trial failure Phase 3 study stock price collapse securities fraud investigation ersodetug congenital hyperinsulinism primary endpoint

Sentiment note

The company's lead therapeutic candidate failed to meet primary and secondary efficacy endpoints in a Phase 3 clinical trial, resulting in an 87.2% stock price decline and triggering a securities fraud investigation. This represents a complete loss of investor confidence and severely diminished commercial prospects for the company's most advanced clinical program.

Negative Mar 18, 2026 • 10:00 UTC GlobeNewswire Inc. • Na

XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements

XOMA Royalty Corporation reported over $50 million in cash receipts for 2025, with royalties up 68% year-over-year. The company added 22 assets to its portfolio, completed seven acquisitions generating $11.7 million in non-dilutive capital, and repurchased 648,048 shares for $16 million. Key 2026 catalysts include Phase 2b/3 data readouts and potential EMA regulatory decisions on commercial assets OJEMDA and MIPLYFFA.

DAWN ZVRA RZLT GOSS biotech royalty aggregator cash receipts portfolio expansion acquisitions

Sentiment note

Phase 3 study of ersodetug for congenital hyperinsulinism failed to achieve statistical significance versus placebo despite showing numerical improvements, requiring FDA meeting to determine next steps for the program.

Neutral Mar 4, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Rezolute to Participate in the Citizens Life Sciences Conference

Rezolute, Inc., a late-stage rare disease company developing ersodetug antibody therapy for hyperinsulinism-induced hypoglycemia, announced it will participate in the Citizens Life Sciences Conference on March 10-11, 2026, in Miami, FL, with management available for one-on-one investor meetings.

RZLT hyperinsulinism hypoglycemia ersodetug antibody therapy rare disease clinical trials investor conference

Sentiment note

The announcement is a routine conference participation notice with no material business developments, clinical trial results, or financial information disclosed. It represents standard investor relations activity without positive or negative implications for the company's prospects.

Negative Feb 9, 2026 • 20:19 UTC GlobeNewswire Inc. • Hagens Berman

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Rezolute, Inc. (NASDAQ: RZLT) experienced a dramatic 90% intraday stock price decline on December 11, 2025, after announcing that its Phase 3 sunRIZE trial for ersodetug failed to meet primary and secondary endpoints for treating hypoglycemia caused by hyperinsulinism. The failure contradicted the company's previous assurances about the drug's efficacy and market potential, prompting shareholder rights firm Hagens Berman to investigate potential investor fraud.

RZLT Phase 3 trial failure stock crash ersodetug hyperinsulinism investor fraud investigation securities litigation clinical trial results

Sentiment note

The company's stock crashed 90% following the announcement that its lead drug candidate failed to meet primary and secondary endpoints in Phase 3 trials, contradicting previous positive investor guidance. This represents a catastrophic loss of shareholder value and has triggered a securities fraud investigation.

Negative Feb 4, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Rezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

Rezolute's Phase 3 sunRIZE study in congenital hyperinsulinism failed to meet its primary and key secondary endpoints. While the top dose of ersodetug (10 mg/kg) showed a 45% reduction in hypoglycemia events compared to 40% in the placebo arm, this marginal difference represents a study failure. The company plans to meet with the FDA regarding the path forward.

RZLT Phase 3 clinical trial congenital hyperinsulinism ersodetug hypoglycemia primary endpoint failure FDA meeting

Sentiment note

The Phase 3 sunRIZE study failed to meet its primary and key secondary endpoints. Although ersodetug showed a 45% reduction in hypoglycemia events at the top dose versus 40% in placebo, this minimal difference (5 percentage points) indicates the drug did not demonstrate statistically significant superiority over placebo, which is a significant setback for the company's late-stage development program.

Negative Feb 4, 2026 • 00:44 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

SHAREHOLDER INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug. The trial failed to meet both primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims on behalf of affected investors.

RZLT clinical trial failure Phase 3 trial ersodetug congenital hyperinsulinism shareholder investigation securities litigation stock decline

Sentiment note

The company's lead drug candidate failed to meet primary and secondary endpoints in a Phase 3 clinical trial, resulting in sharp stock decline and triggering a securities investigation. This represents a significant setback for the company's pipeline and investor confidence.

Negative Jan 20, 2026 • 21:47 UTC GlobeNewswire Inc. • Pomerantz Llp

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA

Pomerantz LLP is investigating potential securities fraud claims against XOMA Royalty Corporation following a significant stock price decline. The investigation was triggered by disappointing Phase 3 trial results from development partner Rezolute for the drug ersodetug, which failed to meet primary and secondary endpoints in treating congenital hyperinsulinism. XOMA's stock fell 22.76% on the news.

XOMA XOMAO XOMAP RZLT securities fraud class action lawsuit Phase 3 trial failure stock price decline

Sentiment note

Phase 3 sunRIZE study for ersodetug failed to meet primary endpoint (45% vs 40% placebo reduction) and key secondary endpoint (25% vs 5% placebo reduction), indicating the drug candidate did not demonstrate statistical significance over placebo.

Negative Jan 3, 2026 • 12:41 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLT

Rezolute, Inc. shares collapsed approximately 85-90% on December 11, 2025, after the company's Phase 3 sunRIZE clinical trial for its lead drug candidate ersodetug failed to meet primary and key secondary endpoints in treating congenital hyperinsulinism. The stock dropped from around $10.94 to an intraday low near $0.90, triggering Nasdaq volatility halts.

RZLT clinical trial failure Phase 3 trial stock collapse congenital hyperinsulinism ersodetug securities litigation

Sentiment note

The company experienced a catastrophic stock price decline of 85-90% due to its lead drug candidate failing to meet primary and secondary endpoints in a Phase 3 clinical trial, representing a major setback for the company's pipeline and investor confidence.

Negative Dec 24, 2025 • 16:50 UTC GlobeNewswire Inc. • Faruqi & Faruqi, Llp

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rezolute

Rezolute's stock plummeted on December 11, 2025, following disappointing results from its Phase 3 sunRIZE clinical trial for ersodetug, a lead drug candidate for congenital hyperinsulinism. The study failed to meet its primary and key secondary endpoints, with the highest dose showing statistically insignificant reductions in hypoglycemia events versus placebo. Securities law firm Faruqi & Faruqi is investigating potential claims against the company on behalf of affected investors.

RZLT clinical trial failure Phase 3 trial stock decline securities litigation congenital hyperinsulinism ersodetug investor losses

Sentiment note

The company's lead drug candidate failed to meet primary and secondary endpoints in Phase 3 trials, resulting in sharp stock decline and triggering securities litigation investigation. This represents a significant setback for the company's pipeline and investor confidence.

Negative Dec 16, 2025 • 23:53 UTC GlobeNewswire Inc. • Na

Rezolute, Inc. (RZLT) Shares Tank 90% Amid Lead Asset Trial Failure -- Hagens Berman Investigating

Rezolute's stock dropped 90% after its Phase 3 trial for ersodetug failed to meet primary and secondary endpoints in treating hypoglycemia caused by hyperinsulinism, prompting a shareholder investigation.

RZLT Phase 3 trial hypoglycemia ersodetug stock crash shareholder investigation

Sentiment note

Stock price crashed 90% due to clinical trial failure, contradicting previous investor assurances about drug efficacy and market potential

Unknown Jun 27, 2024 • 12:00 UTC GlobeNewswire Inc. • Rezolute, Inc.

Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement

Additional $6.7M in funding resulting in approximately $67M in gross proceeds Additional $6.7M in funding resulting in approximately $67M in gross proceeds

RZLT Changes in company's own shares